UroGen Pharma (URGN) Enterprise Value (2016 - 2026)
UroGen Pharma's (URGN) quarterly Enterprise Value came in at -$140.3 million in Q1 2026, up 28.39% YoY from -$109.3 million in Q1 2025, and down 16.45% on a QoQ basis from -$120.5 million in Q4 2025.
UroGen Pharma (URGN) Enterprise Value (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Enterprise Value data on file, last reported at -$140.3 million in Q1 2026.
- Quarterly Enterprise Value rose 28.39% year-over-year to -$140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140.3 million (up 28.39% YoY) and the FY2025 annual result came in at -$120.5 million, up 49.11% from the prior year.
- Enterprise Value retreated to -$140.3 million in Q1 2026, from -$120.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$47.3 million in Q2 2023 to a low of -$249.6 million in Q3 2024.
- A 5-year average of -$143.4 million and a median of -$137.0 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 52.32% — and 2024, when it plunged 409.67%.
- Tracing URGN's Enterprise Value over 5 years: stood at -$100.0 million in 2022, then tumbled by 37.02% to -$137.0 million in 2023, then slumped by 72.8% to -$236.7 million in 2024, then jumped by 49.11% to -$120.5 million in 2025, then dropped by 16.45% to -$140.3 million in 2026.
- The last three Enterprise Value figures came in at -$140.3 million (Q1 2026), -$120.5 million (Q4 2025), and -$127.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -107.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -107.98 Mn |
| Mar 31, 2026 | -140.27 Mn |
| Dec 31, 2025 | -120.46 Mn |
| Sep 30, 2025 | -127.03 Mn |
| Jun 30, 2025 | -156.95 Mn |
| Mar 31, 2025 | -195.89 Mn |
| Dec 31, 2024 | -236.69 Mn |
| Sep 30, 2024 | -249.58 Mn |
| Jun 30, 2024 | -241.08 Mn |
| Mar 31, 2024 | -164.05 Mn |
| Dec 31, 2023 | -136.97 Mn |
| Sep 30, 2023 | -147.42 Mn |
| Jun 30, 2023 | -47.30 Mn |
| Mar 31, 2023 | -65.05 Mn |
| Dec 31, 2022 | -99.96 Mn |
| Sep 30, 2022 | -95.91 Mn |
| Jun 30, 2022 | -77.50 Mn |
| Mar 31, 2022 | -136.44 Mn |
| Dec 31, 2021 | -89.14 Mn |
| Sep 30, 2021 | -106.21 Mn |